This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McIntosh, J. K. Articles by Rosenberg, S. A. Search for Related Content PubMed PubMed Citation Articles by McIntosh, J. K. Articles by Rosenberg, S. A.

Combination Cytokine Immunotherapy with Tumor Necrosis Factor , Interleukin 2, and -Interferon and Its Synergistic Antitumor Effects in Mice

Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892

The antitumor activity of combination therapy with recombinant human tumor necrosis factor (rhTNF-), recombinant human interleukin 2 (rhIL-2), and recombinant hybrid -interferon A/D (rhIFN- A/D) was assessed against established weakly immunogenic (MCA-106) and nonimmunogenic (MCA-102) sarcomas at both s.c. and visceral (hepatic) sites. C57BL/6 mice were treated with a single i.v. dose of rhTNF- followed by rhIL-2 (75,000 units) and rhIFN- A/D (75,000 units) i.p. twice daily for 5 consecutive days. Substantial improvements were observed when the combination of rhTNF-, rhIL-2, and rhIFN- A/D was administered, as measured by regression of tumor, prolongation of survival, and improved cure rates, compared with any combination of two cytokines or any cytokine alone against the MCA-106 sarcoma. These findings were consistent in both the s.c. and single hepatic tumor models. For example, treatment of the MCA-106 s.c. tumor bearers with the triple cytokine combination resulted in cures of 16 of 18, 17 of 18, and 12 of 18 mice receiving rhTNF- dosages of 2, 4, and 6 µg, respectively, compared with 2 of 18, 7 of 18, and 9 of 18 at 2, 4, and 6 µg of rhTNF- plus rhIL-2 without rhIFN- A/D. Established 10-day single liver tumor weights when treated with the triple combination therapy were 54 and 25 mg in treatment groups receiving 2 and 4 µg of rhTNF-, compared with 376 and 302 mg with the same amounts of rhTNF- alone (P < 0.004). Mice bearing hepatic sarcomas treated with triple cytokine combination therapy had cure rates of 50% and 67% at rhTNF- doses of 2 and 4 µg, compared with no survivors with rhTNF- alone. No improved antitumor effects resulted from therapy with any cytokine alone or in combination against the nonimmunogenic MCA-102 sarcoma. Possible in vivo mechanisms by which these three cytokines synergize are discussed.

¹ To whom requests for reprints should be addressed, at Building 10, Rm. 2B42, National Cancer Institute, NIH, Bethesda, MD 20892.

Received 9/ 8/88. Revised 12/ 1/88. Accepted 12/12/88.

This article has been cited by other articles:

				K. Shimizu, R. C. Fields, M. Giedlin, and J. J. Mule Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines PNAS, March 2, 1999; 96(5): 2268 - 2273. [Abstract] [Full Text] [PDF]